Standing-room only at symposium 17 on Sunday on the topic “long-term brain effects of antipsychotic treatment for schizophrenia”. The onCNS correspondent got in early and bagged one of the last remaining seats.

Dr Ofer Agid describes himself as an optimist with a deep interest in patient stories and a desire to help tackle often ‘invisible’ illnesses with a major impact on patient lives. Read our interview with him here.

Guy Goodwin, Professor of Psychiatry at the University of Oxford, UK, and President of the ECNP, addresses the names we use for drug classes and how they can improve or impede our understanding.